Evidence map›Paper›PMID 34291395›Full record

ArticleMolecular biology reports2021

Omeprazole suppresses endothelial calcium response and eNOS Ser1177 phosphorylation in porcine aortic endothelial cells.

Chiaki Kamiya, Keiichi Odagiri, Akio Hakamata, Ryugo Sakurada, Naoki Inui, Hiroshi Watanabe

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Chiaki KamiyaDepartment of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, Japan.
Keiichi OdagiriCenter for Clinical Research, Hamamatsu University Hospital, 1-20-1 Handayama, Hamamatsu, Japan. kodagiri@hama-med.ac.jp.ORCID http://orcid.org/0000-0001-6968-0516
Akio HakamataDepartment of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, Japan.
Ryugo SakuradaDepartment of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, Japan.
Naoki InuiDepartment of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, Japan.
Hiroshi WatanabeDepartment of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, Japan.
Hamamatsu University School of Medicine · JPHamamatsu University · JP

Funding

Hamamatsu University School of Medicine 42351T 1013511Hamamatsu University School of Medicine 42351T 1013522
6 · The paper itself

Abstract

backgroundAlthough high doses of proton pump inhibitors can elicit an anticancer effect, this strategy may impair vascular biology. In particular, their effects on endothelial Ca METHODS AND

resultsOmeprazole (10-1000 μM) suppressed both bradykinin (BK)- and thapsigargin-induced endothelial Ca

conclusionOur results are the first to indicate that high doses of omeprazole may suppress both store-operated Ca

Indexed as

AnimalsAortaBradykininCalciumDose-Response Relationship, DrugEndoplasmic ReticulumEndothelial CellsEndothelium, VascularEpoprostenolNitric OxideNitric Oxide Synthase Type IIIOmeprazolePhosphorylationSwineBradykininCalciumEpoprostenolNitric OxideNitric Oxide Synthase Type IIIOmeprazoleCalciumEndothelial cellsEndothelium-dependent relaxing factorsNitric oxide synthaseOmeprazole

Identifiers

PMID34291395
OpenAlexW3186850470

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.